Mizuho's New Price Target#
Mizuho has raised its price target for Humana stock (NYSE:HUM) from $258 to $290 while keeping an Outperform rating. Currently, Humana's stock is trading at $243.12, reflecting a 5.7% increase over the past week. According to analysis, the stock is considered undervalued, with a fair value estimated at $280.74.
Key Highlights from the Quarter#
The firm pointed to Humana's strong performance in its medical loss ratio, which measures the percentage of premiums spent on medical care. Mizuho also noted the company's cautious approach to estimating its reserves for medical costs, especially given uncertainties around membership growth. Additionally, Humana's balance sheet shows it has more cash than debt, enhancing its financial flexibility.
Analyst Insights#
Mizuho believes that the overall environment for medical costs may be improving, suggesting that the acceleration in medical cost trends could be peaking. The firm has maintained its adjusted earnings per share estimates for 2026-2028 following the recent quarter's results. Analyst Ann Hynes authored the research note supporting these insights.
Recent Financial Performance#
In its latest earnings report for the first quarter of 2026, Humana exceeded expectations with earnings per share (EPS) of $10.31, surpassing the forecast of $10.20. The company also reported revenue of $39.65 billion, exceeding the anticipated $39.37 billion. Despite these positive results, Humana's stock saw a decline in pre-market trading, indicating some investor caution amid broader market conditions. These developments underscore Humana's strong financial performance in the first quarter.